Bloomberg News

Shire to End Free Supply of Replagal in U.S., Spokeswoman Says

March 15, 2012

Shire Plc (SHP) will end the free supply of the Replagal drug for Fabry disease in the U.S. now that production of Sanofi’s competing treatment is returning to normal, a spokeswoman said.

Shire will work with doctors to transition patients to the Sanofi drug, the spokeswoman said by e-mail.

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net


The Good Business Issue
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus